In 2015, Capital International had purchased an 11 percent stake in Mankind Pharma from ChrysCapital for $200 million. In April 2018, a ChrysCapital-led consortium, which included GIC and CPPIB, made a stunning comeback and bought a 10 percent stake again for around $350 million.
The asset manager is in talks with advisers to weigh a tender offer, according to the people, who asked not to be identified discussing confidential information. CPPIB is the controlling shareholder in ReNew, the people said, adding that talks are ongoing and no final decision has been reached.